Fresenius News Not All Bad For Affymax’s Omontys
This article was originally published in The Pink Sheet Daily
Executive Summary
Affymax investors were not pleased with the country’s largest dialysis provider pausing its pilot program of Omontys, but Affymax and analysts are bullish on prospects of a long-term contract developing.